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ABSTRACT 
Ebola hemorrhagic disease is a severe, an acute, often fatal disease in humans and non-humans which is caused by infection with a 
virus of family: Filoviridae, genus: Ebola virus. The incubation period of ebola virus disease (EVD) varies from 2-21 days, with an 
observed average of 8 to 10 days by following introduction of Ebola virus in the human population through animal-to-human 
transmission, person-to-person transmission by direct contact body fluids/secretions of infected persons. The most common 
symptoms include sudden onset of fever, intense weakness, muscle pain, headache and sore throat, vomiting, diarrhea, rash, 
impaired kidney and liver function, and at advanced stage both internal and external bleeding. The virus is transmitted by contact 
with body fluids of infected humans or an animal is primarily responsible for the virus outbreak. Fruit bats are considered as the 
natural reservoirs of the virus. The most general assays used for antibody detection are direct IgG and IgM ELISAs and IgM capture 
ELISA. An IgM or rising IgG titer (four-fold) contributes to strong presumptive diagnosis. Currently neither a licensed vaccine nor 
an approved treatment is available for human use. In this review, the Ebola virus: life cycle and pathogenicity in humans, diagnosis, 
pharmacotherapy and their prevention is summarized. 
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1. INTRODUCTION  
Ebola, previously known as Ebola hemorrhagic disease, 
is a severe, an acute, often fatal disease in humans and 
non-humans. It is a rare and deadly disease caused by 
infection with a virus of family: Filoviridae, genus: 
Ebola virus. There are five identified ebola virus 
species, four of which have caused disease in humans 
known as Ebola Virus Diseases (EVD)
1,2
. Ebola virus 
has caused the majority of human deaths from EVD, and 
is the cause of the 2013-2014 ebola virus epidemics in 
West Africa, which has resulted in at least 20,834 
suspected causes and 8,251 confirmed deaths
1
. There are 
no licensed specific treatments or vaccine available for 
use in peoples and animals. 
There are five identified ebola virus species which differ 
in their virulence for humans i.e. Zaire ebola virus; 
Sudan ebola virus; Tai Forest ebola virus (Cote d’Ivoire 
Ebola virus); Bundibugyo ebola virus caused disease in 
humans and the fifth Reston ebola virus has caused 
disease in nonhuman primates (such as Monkeys, 
gorillas and chimpanzees) but not in humans
1,2
. 
The incubation period of ebola virus disease (EVD) 
varies from 2-21 days, with an observed average of 8 to 
10 days. Following the introduction of Ebola virus in the 
human population through animal-to-human 
transmission, person-to-person transmission by direct 
contact body fluids/secretions of infected persons is 
considered the principal mode of transmission. Indirect 
contact with environment and families soiled with 
contaminated body fluids (e.g needles) may also occur. 
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Airborne transmission has not been documented during 
previous EVD outbreaks. There is no risk of 
transmission during the incubation period. 
The most common symptoms experienced by persons 
infected with the virus are the sudden onset of fever, 
intense weakness, muscle pain, headache and sore 
throat. This is the followed by vomiting, diarrhea, rash, 
impaired kidney and liver function, and at advanced 
stage both internal and external bleeding. Laboratory 
findings include low white blood cells and platelet 
counts and elevated liver enzymes
5
. 
2. EPIDEMIOLOGY 
The filo viruses were first recognized in 1967, when the 
inadvertent importation of infected monkeys from 
Uganda into Germany and Yugoslavia resulted in 
explosive outbreak of severe illness among vaccine 
plant workers who came into direct contact with animals 
by killing them, removing their kidneys, or preparing 
primary cell cultures for polio vaccine production
6
. 
EVD first appeared in 1976 in two simultaneous 
outbreaks, one in Nzara, Sudan and other in Yambuku, 
Democratic republic of Congo. The latter occurred in a 
village near the Ebola River, from which the disease 
takes its name
1
.  
Ebola virus was first discovered in 1976. There have 
been more cases and deaths in the outbreak than all 
others combined. It has also spread between countries 
starting in guinea then spreading across land borders to 
Sierra Leone and Liberia, by air(one traveller only) to 
Nigeria, and by land (one traveler ) to Senegal
1
.  
2014 outbreak in West Africa- By far, the largest 
outbreak of Ebola virus disease ever recorded is 
currently occurring in West Africa with the Zaire 
species of the virus
6-13
. Although most previous Ebola 
outbreaks occurred in central Africa, this outbreak 
started in the West Africans nation of Guinea in late 
2013 and was confirmed by the World health 
organization (WHO) in March 2014
7,14
. The initial case 
was a 2 year old child in Guinea, who developed fever, 
vomiting, and black stools, without other evidence of 
hemorrhage
5
. The outbreak subsequently spread to 
Liberia, sierra Leone, Nigeria, Senegal and Mali
15-17
. 
Sequence analysis of viruses isolated from patients in 
Sierra Leone indicates that the epidemic has resulted 
from sustained person-to-person transmission, without 
additional introductions from animal reservoirs
18
. The 
case –fatality rate has been estimated to be 
approximately 70 percent
19
. 
As of October 19, 2014, the cumulative number of 
portable, suspected, and laboratory –confirmed cases 
attributed to Ebola virus is 9936, including 4877 
deaths
20
. These include 443 health care workers, of 
whom approximately 55 percent have died. However, 
Nigeria and Senegal have not reported any new cases 
since September 5, 2014, and respectively
20-23
. 
Cases of Ebola virus disease related to this outbreak 
have also been reported outside of West Africa. On 
September 30, 2014, the first travel-associated case of 
Ebola was reported in the United States
24
. An individual 
who traveled from Liberia to Dallas, Texas first 
developed clinical findings consistent with ebola virus 
disease approximately five days after arriving in the 
United States. The patient was asymptomatic prior to 
and during the flight. Two health care workers involved 
in the care subsequently developed ebola virus disease
25
. 
So, it was concluded to say that person to person 
transmission was for this disorder. 
2014 outbreak in the democratic republic of Congo- 
In august of 2014, an outbreak of Ebola virus disease 
was reported in the democratic republic of Congo
26,27
. 
The index case was a pregnant woman who prepared 
bush meat from an animal that had been killed by her 
husband. As of October 20, 2014, a total of 66 cases of 
EVD (confirmed and probable), including 49 deaths, 
have been connected to this outbreak
20
. 
Outbreak in India: India which had so far remained 
unscathed from the virus, has diagnosed a fresh case of 
it after an Indian, semen sample showed traces of ebola 
virus. The man, a 26 year old Indian, working in 
Liberia, was earlier treated and cured of the deadly 
virus, is kept in isolation at delhi’s airport health 
organization quarantine centre
28,29
.  
2.1. Virus Reservoir 
The natural reservoir host of Ebola has not yet been 
identified; the manner by which the virus first appears in 
a human at the start of an outbreak is unknown. Perhaps 
the greatest mysteries regarding the filoviruses are the 
identity of their natural reservoir and the mode of 
transmission from the reservoir to wild apes and 
humans. When an infection does not occur in humans, 
there are several ways the virus can be spread to others
 
5,30
. 
3. TRANSMISSION 
Experiments in laboratory animals indicate that 
filoviruses can initiate infection via many routes, 
including ingestion, inhalation, or passage through 
breaks in the skin
31. Non human’s primates can be 
infected with Ebola or Marburg virus through droplet 
inoculation of virus into the mouth or eyes, suggesting 
that cases of human infection result from the inadvertent 
of virus to these sites from the patient’s own 
contaminated hands
32,33
.
 
3.1. Person to person- Person to person transmission 
occurs through direct contact of broken skin or 
unprotected mucous membranes with virus-containing 
body fluids like blood feces and vomit from which  the 
developed signs and symptoms of illness
34
. The viruses 
that cause Ebola are often spread among families and 
friends, because they come in close contact with blood 
or body fluids when caring for ill person. It has been 
also detected in urine, semen and breast milk. Saliva and 
tears also harbor the virus. Thus, contact with any of 
these fluids can pose potential risk. During the outbreak 
of Ebola, the disease can spread quickly with in 
healthcare settings, such as clinics or hospitals
10
. 
3.2. Direct contact with the objects (like needles and 
syringes) that have been contaminated with the blood or 
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body fluids of an infected person or with infected 
animals. 
Ebola virus may also be transmitted though contact with 
previously contaminated surfaces and objects. Limited 
data suggest that viable virus may exist for upto several 
days on fomities. Although there are no high- quality 
data to confirm transmission through this type of 
exposure, the potential risk can be reduced by proper 
environmental learning
2
.  
4. INCUBATION PERIODS 
patients with EVD typically have an abrupt of 
symptoms 8-12 days after exposure (range 2 to 21 
days)
35,36
. However, all symptomatic individuals should 
be assumed to have high levels of virus in the blood and 
other body fluids and appropriate safety precaution 
should be taken
37
. 
5. SYMPTOMS AND SIGNS 
the most common sign and symptoms reported from 
west Africa during the 2014 outbreak include: fever (85 
percent), fatigue (76 percent), vomiting (68 percent), 
diarrhea (66 percent) and loss of appetite (65 percent)
35
. 
Important clinical findings of patients with Ebola and 
Marberg virus disease are as follows: 
 Nonspecific flu-like symptoms- Ebola and Marberg 
hemorrhagic fever typically begin with the abrupt 
onset of fever, chills and general malaise. Other 
signs and symptoms include weakness, anorexia, 
severe headache, and pain in the muscles of the trunk 
and lower back
38
. Multisystem involvement follows 
that includes prostration; nausea, vomiting, 
abdominal pain, diarrhea and pancreatitis; chest pain, 
cough, and pharyngitis; vascular and neurological 
manifestations.  
 Rash- some patients develop a diffuse eruthematous, 
nonpruritic maculopapular rash by day five to seven 
of illness. The rash usually involves the face, neck, 
trunk, and arms, and can desquamate in servivors
38-
42,4
. 
 Gastrointestinal- gastrointestinal signs and 
symptoms usually develop several days after the 
initial presentation. These include watery diarrhea, 
nausea, vomiting, and abdominal pain. 
 Hemorrhage- bleeding is often not observed in the 
early phase of illness, but may manifest later in the 
course of disease as petechiae, ecchymosis/bruising, 
oozing from vein puncture sites, or mucosal 
hemorrhage. During the outbreak in West Africa, 
approximately 20 percent of patients have 
unexplained bleeding, which is the most commonly 
manifested as blood in the stool (about 6 percent)
35
. 
 Other findings- patients with Ebola virus disease 
can persist with addition findings such as hiccups, 
chest pain, shortness of breath, headache, confusion, 
seizures, and cerebral edema. Liver failure, multi-
organ dysfunction, conjunctival infection and dark 
red discoloration of the soft palate are other common 
physical findings
4
. 
In non-fatal cases, patients typically improve 
approximately 6 days after the onset of symptoms. The 
formation of antigen-antibody complexes during 
recovery may cause acute arthralgias and other 
symptoms. Fatal disease has been characterized by more 
severe clinical signs early during infection and 
progression to multi-organ failure and septic shock. 
Death typically occur between days six and sixteen 16
31
. 
Ebola virus: life cycle and pathogenicity in humans:- 
 
The much-talked about Ebola virus is an encapsulated 
single-stranded (ss) negative RNA virus belonging to 
the family Filoviridae.  
 Cell and Molecular Biology: 
Electron microscopy studies show that the Ebola virus 
has a filamentous appearance typically 800 nm long and 
80 nm in diameter. Each viral particle or virion consists 
of a nucleocapsid consisting of the negative ssRNA 
genome surrounded by the nucleoprotein NP, the 
polymerase cofactor VP35, the virus specific 
transcription activator VP30, and the viral RNA 
polymerase L protein (fig 1). This nucleocapsid is 
encapsulated by an outer viral envelope originating from 
the host cell membrane with characteristic 10 nm long 
viral glycoprotein (GP) spikes. The matrix between the 
outer viral envelope and the nuclecapsid is occupied by 
the VP40 and VP24 viral proteins
43
. 
In green is the nucleocapsid made of the ssRNA     
genome and the proteins NP (large green spheres), VP35 
(in purple), VP30 (in blue) and L (in grey) proteins. 
Note that the NP or N, VP35 and L proteins are shown 
outside the virion for better visibility. The nucleocapsid 
is surrounded by the outer membrane derived from host 
cell membrane (in light blue) and is studded with viral 
GP spikes (yellow studs). The matrix between the 
nucleocapsid and the outer membrane (in brown) 
comprises of the VP40 (brown) and VP24 (orange) 
proteins.  Source: Viral Zone (ExPASy).
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Figure 1: Schematic representation of the Ebola virus. 
The virus genome is 19 kb (kilobases) in length, and encodes seven structural and one non-structural protein. The fig 
below shows the virus genome with the gene order.  
 
Figure 2: Diagrammatic representation of the Ebola virus genome. 
The leader and the trailor regions are untranscribed 
sequences which regulate transcription, replication and 
packaging of genomes into new virions.  
The viral RNA polymerase binds at the leader end to 
initiate sequential transcriptional of each gene. The 
newly transcribed mRNAs are capped and 
polyadenylated by the L protein during this process. Of 
note, the primary mRNA transcribed from the GP gene 
encodes a small, non structural, soluble protein called 
sGP which is secreated from the infected host cells into 
blood. The fully functional glyprotein is a result of RNA 
editing and this protein is expressed on the cell surface 
as GP spikes
44
. These GP spikes, help in anchorage and 
membrane fusion of the virion to the host cell, and are a 
crucial factor for ebola virus pathogenicity. 
The matrix protein VP40 is important for maintaining 
the structural integrity of the virion. It is also associated 
with endocytosis and virus budding and has the ability 
to release itself from the cells even in the absence of 
other viral proteins
45
. The second matrix protein VP24 
suppresses interferon production in the host cell
46
. In 
remaining proteins namely NP, VP35, VP30 and L 
proteins from the structure components of the 
nuclecapsid. More, these proteins also catalyse genome 
transcription and replication
47
. 
6. VIRUS TRANSMISSION 
It is not entirely known how Ebola spreads in humans, 
but contact with body fluids of infected humans or 
animals is primarily responsible for the virus outbreak. 
Fruit bats are the natural reservoirs of the virus. The US 
centre for Disease Control has a self-explantory cartoon 
depicting the likely method of virus transmission from 
bats to humans. Fig 3. 
7. THE LIFE-CYCLE OF THE VIRUS 
(1) Host immune system attack  
The early targets of the virus are the monocytes and the 
macrophages of the host immune system and other 
target cells are liver cells, and endothelial cells. Ebola 
virus employs different mechanisms to interfere with or 
even ignore the host immune system completely. Most 
of these host immune system attack processes involve 
the virus structural proteins. One such mechanism is 
called the antibody-dependent enhancement (ADE) 
wherein the host antibodies (Abs), facilitate or enhance 
the virus’s attachment to the host cells increasing 
infection in these cells. The Abs bind to antibody 
receptors at their Fc sites while the virus binds to the 
antigen-binding site at the free end of the Abs
48
. In vitro 
studies in Ebola showed that the virus activates the 
classical pathway of the complement system. Initially, 
the Ebola virus binds to its receptor on the host cell 
surface. Following this, Abs bind to the glycoprotein 
(GP) spikes of the virus, and the C1q component of the 
complement enhances the Ab-GP complex to bind to 
C1q ligands on the host cell surface thus increasing the 
interaction of the host cell surface. This way, the GP 
spikes on the virus use the host immune system (Abs 
and the complement components) to enhance its 
attachment to the target cells
49
.
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Figure 3: Ebola virus transmission from fruit bats to humans. 
The virus is transmitted by contact with contaminated 
body fluids. Figure 3: Ebola virus transmission from 
fruit bats to humans.  
In addition to ADE, the virus protein VP35, blocks the 
immune system’s interferon (IFN) pathways comprising 
of various cytokines that exert anti-viral responses.VP35 
blocks IFN response by competing with the protein such 
as retinoic acid -inducible gene 1 (RIG1) protein to 
activate the IFN pathway
50
. Along with VP35, VP24 
also blocks IFN pathway activation. VP24 blocks 
transcription factors like STAT1 that regulate 
transcription of the immune system genes4. 
As aforementioned, the primary mRNA transcript of the 
GP gene encodes the soluble sGP which is speculated to 
have an anti-inflammatory role during infection which 
further enhances the virus’ escape from host immune 
system response. Moreover, sGP has many similar 
epitopes with GP, so it could potentially sequester or 
absorb host Abs to block their downstream action
54,55
. 
Thus, the viral proteins disrupt different components of 
the immune system to attach to the host cell for 
subsequent entry. In this way, it attacks the immune 
system of the host cell. 
(2) Virus entry into the host cell 
The exact mechanism by which the Ebola virus enters 
host cells remains poorly understood. One general 
mechanism to infect host cells for most enveloped 
viruses including the Ebola virus is Endocytosis. 
Research indicates that the virus utilises a lipid-
dependent, non-clathrin and dynamin-independent 
endocytic pathway of entry. Macropinocytosis is the 
most likely mechanism employed by the Ebola virus
56
. 
This process involves outward extensions of the plasma 
membrane formed by actin polymerization, which can 
fold back upon themselves. The distal loop ends of these 
extensions or membrane ruffles can fuse to form a 
macriopinosome. This also means that actin and its 
associated polymerising proteins play a pivotal role in 
virus entry. The exact mechanism by which the virus 
induces macropinocytosis is not understood. It is 
speculated that interactions between GP and host cell 
surface receptors can trigger macropinocytosis to initiate 
viral entry
56
. 
(3) Virus replication 
Once inside the host cell, the virus initiates transcription 
at the leader end of the genome with the binding of the 
polymerase complex5. VP30 is an important 
transcription activation factor for viral genome 
transcription, while VP24 is an inhibitor to this process. 
The exact mechanism of VP24-dependent transcription 
termination is not fully understood, but it seems to be 
important for converting the virus from its 
transcriptional or replication active form to one that is 
geared for virion assembly and exit from host cell
55
. 
(4) Virus budding and exit from host cell 
Following replication, the cell loses its connection with 
other cells as well as attachment to its substrate. 
Meanwhile, the newly synthesized genomes are 
packaged into new buds or virions and egresses from the 
host cell surface with the help of the matrix protein 
VP40. VP40 interacts with ubiquitin ligase Nedd4 which 
is a part of human ubiquitination enzyme pathway and 
links multiple copies of ubiquitin molecules to VP40
57
. 
VP40 itself is transported to the host cell plasma 
membrane using the COPII transport system
55
. Once in 
the plasma membrane, the virus moves through lipid 
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rafts where the final assembly and budding of the virions 
occur, before their final exit from the host cell. 
Although the structural components of the virus are 
known, the exact mechanisms by which it causes disease 
in humans are not completely understood. This poses a 
major challenge for treatment and to date prevention is 
the best mode of action to avoid an Ebola outbreak.  
 8. DIAGNOSIS  
It can be difficult to distinguish EVD from other 
infectious diseases such as malaria, typhoid fever and 
meningitis because a Confirmation that symptoms are 
caused by Ebola virus infections are made using the 
following investigations
57-61
:
 
Timeline of infection Diagnostic tests available 
Within a few days after symptoms begin -antigen capture enzyme-linked immunosorbent assay(ELISA) testing 
-igM ELISA 
-polymerase chain reaction (PCR) 
-virus isolation 
Later in disease course or after recovery -igM and igG antibodies 
Retrospectively in deceased patients -immunohistochemistry testing 
-PCR 
-Virus isolation 
 
Ebola Virus: Development of Vaccines and 
Therapeutic Drugs
62 
The 2014 outbreak of Ebola virus highlights the urgent 
need to develop an effective vaccine to prevent the 
spread of this deadly virus, and effective therapies to 
improve survival rates among those infected with EVD. 
A DNA vaccine candidate should begin clinical trials in 
humans this year, and investigational drugs in 
development to treat patients suffering from viral 
hemorrhagic fever include monoclonal antibodies, 
siRNA-based therapeutics, and antiviral small molecule 
drugs
63
. 
Tekmira’s siRNA-based investigational drug TKM-
Ebola has been authorized by FDA under expanded 
access protocols to be administered to patients 
diagnosed with or suspected to be infected with Ebola
63
. 
Recent Research Reports on Ebola
63
: 
 In April 2014, a group of researchers from the CDC 
published a study on High-throughput, luciferase-
based reverse genetics systems for identifying 
inhibitors of Margburg and Ebola viruses, using 
codon-optimized Ebola virus genes synthesized by 
Genscript. 
 A 2013 Molecular therapy paper report pre-clinical 
results for a DNA vaccine that protects against Ebola 
and Marburg in guinea pigs and rodents. Inovia 
Pharmaceuticals is using its SynCon platform to 
develop synthetic gene-based vaccine against Ebola, 
HIV, cancer-causing viruses, and   influenza. 
 London, Jan 06 (IANS) Oxford University doctors 
and scientists are starting the first safety trial of an 
experimental preventative Ebola vaccine, aiming to 
have vaccinated all 72 healthy adult volunteers by 
the end of January. Volunteers for the trial, aged 
from 18-50, will be the first humans to receive the 
vaccine, which is developed by Janseen 
Pharmaceutical Companies of Johnson and Johnson, 
Xinhus reported citing a press release from the 
university issued Tuesday. The study involves a 
prime-boost vaccine regimen, which does not contain 
any replicating virus, so it in not possible to be 
infected with Ebola, according to the researchers. 
Patients are first given a prime immune system to 
stimulate an initial immune response, and then a 
boost intended to further enhance the level of the 
body’s immune response over time64.    
New Ebola Drugs Cures Monkeys in Clinical Trial
62 
The cure of the fatal Ebola virus may finally have just 
been discovered. Recently, there has been reports by 
scientists of Ebola-infected monkeys being completely 
cured. The medication, Zmapp, is at present being used 
to treat patients infected with the virus including 
William Pooley-a British nurse- who is currently being 
treated at London-based Royal Free hospital for 
contacting the disease in Sierra Leone
62
. 
Around 18 monkeys infected with Ebola were found to 
be totally cured after being administered ZMapp. The 
results, according to experts, were heavily encouraging. 
The result revealed that these trials now have a strong 
backing and should be used in humans. On the other 
hand, it should be noted that two patients treated with 
the drugs had died, but it may have been because the 
drug was administered too late for it to be effective
62
.
  
 
Ongoing Ebola Drug Development efforts
63
: 
 Newlink Genetics Crop is poised to begin the first 
clinical trials of an Ebola vaccine an attenuated live 
virus, vesicular stomatitis virus (VSV), a common 
livestock pathogen, into which an Ebola viral coat 
protein has been introduced
63
.  
 A vaccine currently poised to begin clinical trials as 
soon as 2014 is a DNA vaccine, containing synthetic 
genes encoded by the Ebola virus delivered in a non-
replicating adenoviral vector. DNA vaccine 
stimulates a robust immune response to high-level 
expression of specific antigenic proteins delivered in 
vector optimized for safety
63
.  
 DNA vaccine efficacy can be enhanced through co-
delivery of synthetic genes encoding adjuvants such 
as cytokinins, chemokines, or synthetic genes 
encoding
63
. 
Taneja et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2018; 8(3): 124-132                
ISSN: 2250-1177                                                                              [130]                                                                            CODEN (USA): JDDTAO 
 Researchers at the NIH’s Vaccine Research Center 
(VRC) have designed a DNA vaccine against Ebola 
in collaboration with Okairos, which was recently 
acquired by GSK. This vaccine candidate is 
composed of a non-replicating chimpanzee 
adenovirus vector vaccine into which two Ebola 
genes have been inserted.  Clinical trials are expected 
to begin in fall 2014 with approval coming soon as in 
2015
63
. 
 Several investigational drugs have received FDA 
permission to be administered to patients infected 
with Ebola virus, including the monoclonal 
antibodies cocktail ZMapp and the RNA based 
therapeutic TKM Ebola
63
.  
 siRNA delivered through lipid nanoparticles: 
Tekrima is developing the RNAi-based therapeutic 
TKM. Ebola to combact the Zaire species of ebola 
virus (ZEBOV)
63
. 
Prevention and control 
Contact tracing, a good laboratory service, safe burials 
and social mobilization
1
. Raising awareness of risk 
factor among people against EBOLA virus and their 
preventive measures if you must travel to an area 
affected by the 2014 EBOLA outbreak, protect yourself 
by doing the following
1
:  
 Wash hand frequently or use an alcohol-based hand 
sanitizer. 
 Avoid contact with blood and body fluids of any 
person, particularly someone who is sick. 
 Do not touch the one who has died from Ebola. 
 Do not touch bats and nonhuman primates or their 
blood and fluids and do not touch or eat raw meat 
prepared from these animals. 
Other protective measures also are taken by individuals 
in an effective way to reduce human transmission. Risk 
reduction messaging should focus on several factors
65,66
 
 Reducing the risk of wildlife-to-human transmission 
from contact with infected fruit bats and 
monkeys/apes and the consumption of their raw 
meat. Animals should be handled with gloves and 
other appropriate protective clothing. Animal 
products (blood and meat) should be thoroughly 
cooked before consumption. 
 Reducing the risk of human-to-human transmission 
with direct or close contact with people with EVD 
symptoms, particularly with their body fluids. 
Gloves and appropriate personal protective 
equipments should be worn when taking care of ill 
patients at home. 
 Outbreaks containment measures including prompt 
and safe burial of dead, identifying people who may 
have been contact with someone infected with Ebola, 
monitoring the health of contacts for 21 days, the 
importance of separating the healthy from the sick to 
prevent further spread, the importance of good 
hygiene and maintaining a clean environment. 
 Information for patients- upto date offers two types 
of patient education materials, “The Basics” and 
“Beyond the Basics.” The Basics patient education 
pieces are written in plain language, at the 5
th
 to 6
th
 
grade reading level, and they answer the four or five 
key questions patient might have about a given 
condition. Beyond the Basics patient education 
pieces are longer, more sophisticated, and more 
detailed. These articles are written at the 10
th
 to 12
th
 
grade reading level and are best for patients who 
want in-depth information and are comfortable with 
some medical jargon.   
SUMMARY AND CONCLUSION 
Last year 2014 was very drastic for the people who 
suffered from Ebola virus disease. Our motive to write 
this review article is only to give the tribute for the 
patients or persons who died from ebola virus and 
another is to spread the awareness amongs the peoples 
for ebola virus by giving their information to the 
patients and peoples related to their sign and symptoms, 
diagnose, treatment and precautions for protecting 
ourself from this disease. 
From this article we concluded that the EVD is 
controlled by either increasing the immune system of 
the human body by taking Basil leaves and fruits as 
immunity boosters or by inhibiting the replication of the 
virus in the host cell by producing Ebola vaccines which 
is going on research work. More rapidly exiting the 
virus from the host cell increases the prognosis of the 
host life is also finding to controlled the EVD. 
Currently no vaccine is produced for the EVD but most 
of the drugs and vaccine are ongoing Ebola Drug 
Development efforts. If any vaccine or drug will 
produce, this article will be updated.
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